U.S. Department of State

OMB No. 1405-0113 EXPIRATION DATE: 09/30/2024

			TUBERCULOS	SIS WORKS	SHEE	T		TIMATED BURD e Page 2 - Back	en: 15 MINUTES of Form)		
Photo		Surnames	Surnames Given Names					Age			
		Birth Date (mm-dd-yyy	y) Document Type	Document Type Doc		umber	С	Case or Alien Number			
		Mediated Immunity to Tubo losis Technical Instructions,		type only, and attacl	h results						
ı	<u> </u>	ned, mark which test:	QuantiFERON (ind [IU/ml] for each)	licate optimal density	y value	T-Spot (indicate spot count for each)					
	= -	Spot	Nil Control:			Nil	Control:				
Dat	e drawn <i>(mm</i>	n-dd-yyyy)	TB Antigen1:			F	Panel A:				
F	Positive Negative		TB Antigen2:			F	Panel B:				
Indeterminate, Borderline, or Equivocal		Mitogen:			Positive	Control:					
2. 0	hest X-Ray	Indication (Mark all that app	oly)	_	_						
Ē	_	Ray not indicated	Known HIV infection		Histor	ry of Tub	erculosis				
Age ≥ 15 years Signs or symptoms of tuberculosis			☐ Extrapulmonary tuberous IGRA positive	Extrapulmonary tuberculosis IGRA positive					st X-Ray Taken <i>yyy)</i>		
3. C	hest X-Ray	Findings (for radiologist to	complete all of Section 3)								
	Normal Findings Abnormal Findings (Indicate category and finding, marking all that apply in the tables below) Suggests Tuberculosis (Need Smears and Cultures) Does Not Need Smears and Cultures										
Г] Infiltrato	or consolidation	Miliary findings)	Mark as	Does N Class E		Do Not Mark as Class B			
F	=	markings suggestive of fibro	_	citv		n DS-20	-	ner on DS-2			
Cavitary lesion Nodule(s) or mass with poorly defined				Discrete nodule(s) without calcification Volume loss or retraction				Smooth pleural thickening (if at CPA, must confirm is not effusion [do lateral or decubitus radiograph or ultrasound])			
			Volume loss or retr				eletal 🗀 🗀				
margins (se		(such as tuberculoma)	Irregular thick pleur	regular thick pleural reaction			Sifty in 🗀	Diaphragmatic tenting Single or scattered calcified pulmonary			
F			Other	Remarks			nodule(s) Calcified lymph node(s)				
Rac	Hilar/mediastinal adenopathy Calcified lymph node(s) Radiologist's Remarks										
		Padialagist's Name (Drintad)	Dodio	lagiatia Cignatura /F	Dogwing dl		Doto In	tornroted (m	m dd i a a a i		
4 9	Radiologist's Name (<i>Printed</i>) Radiologist's Signature (<i>Required</i>) Date Interpreted (<i>mm-dd-yyyyy</i>) 4. Sputum Smears and Cultures Decisions										
Г	_			nown HIV infection.	and:						
_	No, not indicated -Applicant has no signs or symptoms of TB, no known HIV infection, and: X-ray Normal or 'No specimens required' and test for cell-mediated immunity to TB negative (if performed)										
	X-ray	Normal or 'No specimens re	equired' and test for cell-med	iated immunity to TE	B positive	(if perfo	rmed)				
Г	7 Yes are	indicated - Applicant has (Ma	ark all that apply):								
_	_	s or symptoms of TB		Extrapulmonary T	ГВ						
		t X-ray suggests TB		End of treatment							
	Know	n HIV Infection									
5. S	Sputum Sme	ars and Cultures Results									
		Date specimen obtained	Date smear result rep	ported	Р	ositive	Negative				
	Sputum Smear	(<i>mm-dd-yyyy</i>) 1.	(mm-dd-yyyy)					1			
	Results	2.						1			
		3.						1			
	Sputum	Date specimen obtained (mm-dd-yyyy)	Date culture result rep		2054 P	ositive	Negative	NTM	Contaminated		
	Culture	1.									
	Results	2.									
		3.		<u> </u>							

Ар	perculosis Classification plicants can be both Class B1 and Class B3, or Class B2 and Class B3. However, other combinations of tuberculosis classifications are not mitted.							
	No TB Classification CXR not suggestive of tuberculosis, no tuberculosis signs or symptoms, no known HIV infection, TST or IGRA negative (if performed), not a contact							
	Class A Applicant has tuberculosis disease							
	Class B0, TB, Pulmonary Diagnosed with tuberculosis by the panel physician or presented to the panel physician while on tuberculosis treatment and successfully completed DGMQ-defined DOT							
	Class B1 TB, Pulmonary CXR suggests tuberculosis, or tuberculosis signs and symptoms, or known HIV infection and sputum smears and cultures are negative and not a clinically diagnosed case.							
	Class B1 TB, Extrapulmonary Applicants with evidence of extrapulmonary tuberculosis. The anatomic site of infection should be documented.							
	Anatomic Site of Disease No treatment Current treatment Completed treatment Started but did not finish extrapulmonary treatment							
	Class B2 TB, LTBI Evaluation Applicants who have a tuberculin skin test >10 mm or positive IGRA but otherwise have a negative evaluation for tuberculosis. Contacts with TST > 5 mm or positive IGRA should receive this classification (if they are not already Class B1 TB, Pulmonary).							
	No LTBI treatment Current LTBI treatment Completed LTBI treatment Started but did not finish LTBI treatment Dates of treatment							
	Class B3 TB, Contact Evaluation Applicants who are a recent contact of a known tuberculosis case.							
	□ No preventive treatment □ Window Prophylaxis □ Isoniazid □ Rifampin □ 3HP □ Other Dates of treatment to							
	Source Case:							
	Name							
	Case or Alien Number, if known							
	Relationship to Contact							
	Date Contact Ended (mm-dd-yyyy)							
	Type of Source Case TB (Mark only one and attach DST results) Pansusceptible TB MDR TB (resistant to at least INH and rifampin) Drug-resistant TB other than MDR TB Culture negative Culture results not available DST results not yet available							
Rema	rks							

DS-3030 Page 2 of 4

	· -	with Class A TB by the par ent at the time of presenta		edical examinatio	n	
v was the diagn	_	ive laboratory tests	Clinical di			
iagnostic Ches	t Radiograph					
Facility perfo	rming chest radiograph	ı:				
Date Radion	ranh ohtained <i>(mm-dd-</i>	уууу):				
		<i>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</i>				
ndings Present				(11		
Normal or no findings suggestive of tuberculosis				Hilar/mediastina	l adenopat	hy
Infiltrate	e or consolidation		<u> </u>	Miliary findings		
Reticula	ar marking suggestive o	of fibrosis		Discrete linear o	pacity	
Cavitary	y lesion			Discrete nodule(s) without	calcification
☐ Nodule	(s) or mass with poorly	defined margins (such as		Volume loss or r	etraction	
tubercu		J ,	一	Irregular thick pl	eural reacti	ion
Pleural	effusion			Other	ourur rouot	.011
nutum Smear F	Result at Diagnosis			Other		
	men obtained	Date results reported				
(mm-c	dd-yyyy)	(mm-dd-yyyy)		ve Negative		
	December 1 Diaments					
'	Result at Diagnosis	Date results reported				
Date specimen obtained (mm-dd-yyyy)		(mm-dd-yyyy)		ve Negative	NTM Contamir	
	To a Decolle					1
	ty Test Results	Date specimer	n obtained	Date D	ST reporte	d
M	ethod of DST:	(mm-dd-)	ууу)	(mm	m-dd-yyyy)	
MGIT [Agar LJ					
	D	rug		Susceptible	Res	sistant
	Isoniazid					
	Rifampin					
Required for	Ethambutol					
Required for first-line DST						
	Pyrazinamide					
first-line DST	Pyrazinamide Ethionamide					
first-line DST Required for	Pyrazinamide Ethionamide Amikacin					
	Pyrazinamide Ethionamide Amikacin Capreomycin	cid (PAS)				
first-line DST Required for multidrug-	Pyrazinamide Ethionamide Amikacin Capreomycin Para-aminosalicylic a					
Required for multidrug-resistant	Pyrazinamide Ethionamide Amikacin Capreomycin Para-aminosalicylic a Fluoroquinolone, spe					
Required for multidrug-resistant	Pyrazinamide Ethionamide Amikacin Capreomycin Para-aminosalicylic a					
Required for multidrug-resistant	Pyrazinamide Ethionamide Amikacin Capreomycin Para-aminosalicylic a Fluoroquinolone, spe					
Required for multidrug-resistant	Pyrazinamide Ethionamide Amikacin Capreomycin Para-aminosalicylic a Fluoroquinolone, spe					

DS-3030 Page 3 of 4

listory of Class A TB, Continu	ed								
Vere molecular tests used in add	dition to the	required s	putum sm	nears, cultu	ıres, and E	DST:			
No									
Yes (mark all that apply):									
	Mycobacterium Tuberculosis		Rifampin Resistance		Isoniazid Resistance				
Molecular Test	Positive	Negative	Positive	Negative	Positive	Negative			
Hain Line Probe Assay								Performed, attach results	
GeneXpert								Performed, attach results	
Other_							Performed, attach results		
Tuberculosis Treatment	•								
Treating physician or institution	ı								
Approved DOT site:									
Unapproved TB treatmen	t site:								
Drug	Dosage			Start Date (mm-dd-yyyy			End Date (mm-dd-yyyy)		
Isoniazid									
Rifampin									
Ethambutol									
Pyrazinamide									
Other, specify:									

PAPERWORK REDUCTION ACT AND CONFIDENTIALITY STATEMENTS

PAPERWORK REDUCTION ACT STATEMENT

Public reporting burden for this collection of information is estimated to average 15 minutes per response, including time required for searching existing data sources, gathering the necessary documentation, providing the information and/or documents required, and reviewing the final collection. You do not have to supply this information unless this collection displays a currently valid OMB control number. If you have comments on the accuracy of this burden estimate and/or recommendations for reducing it, please send them to: PRA_BurdenComments@state.gov

CONFIDENTIALITY STATEMENT

INA Section 222(f) provides that visa issuance and refusal records shall be considered confidential and shall be used only for the formulation, amendment, administration, or enforcement of the immigration, nationality, and other laws of the United States. The U.S. Department of State uses the information provided on this form to determine an individual's eligibility for a U.S. visa. Certified copies of visa records may be made available to a court which certifies that the information contained in such records is needed in a case pending before the court. The information provided may also be released to federal agencies for law enforcement, counterterrorism and homeland security purposes; to Congress and courts within their sphere of jurisdiction; and to other federal agencies who may need the information to administer or enforce U.S. laws. Although furnishing this information is voluntary, individuals who fail to submit this form or who do not provide all the requested information may be denied a U.S. visa or experience processing delays.

DS-3030 Page 4 of 4